絞り込み

16555

広告

Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.

著者 Kurdi AT , Glavey SV , Bezman NA , Jhatakia A , Guerriero JL , Manier S , Moschetta M , Mishima Y , Roccaro A , Detappe A , Liu CJ , Sacco A , Huynh D , Tai YT , Robbins MD , Azzi J , Ghobrial IM
Mol Cancer Ther.2018 Apr 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (127view , 0users)

Full Text Sources

Elotuzumab, a recently approved antibody for the treatment of multiple myeloma (MM), has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells towards myeloma cells. The modulatory effects of elotuzumab on other effector cells in the tumor microenvironment, however, has not been fully explored. Antibody dependent cellular phagocytosis (ADCP) is a mechanism by which macrophages contribute to anti-tumor potency of monoclonal antibodies. Herein, we studied the NK cell independent effect of elotuzumab on tumor associated macrophages (TAMs) using a xenograft tumor model deficient in NK and adaptive immune cells. We demonstrate significant anti-tumor efficacy of single agent elotuzumab in immunocompromised xenograft models of multiple myeloma, which is in part mediated by Fc-FcγR interaction of elotuzumab with macrophages. Elotuzumab is shown in this study to induce phenotypic activation of macrophages in-vivo and mediates ADCP of myeloma cells though a FcγR dependent manner in-vitro. Together, these findings propose a novel immune mediated mechanism by which elotuzumab exerts anti-myeloma activity and helps to provide rationale for combination therapies that can enhance macrophage activity.
PMID: 29654064 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード